Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 81907-62-2 Chemical Structure| 81907-62-2

Structure of Ganoderic acid A
CAS No.: 81907-62-2

Chemical Structure| 81907-62-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ganoderic acid A, a natural product isolated and purified from the fruit body of Ganoderma lucidum, exhibits antitumor activity.

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ganoderic acid A

CAS No. :81907-62-2
Formula : C30H44O7
M.W : 516.67
SMILES Code : CC1(C)C(CC[C@]2(C)C3=C([C@@]4([C@@H](O)C[C@@H]([C@]4(CC3=O)C)[C@H](C)CC(C[C@@H](C)C(O)=O)=O)C)[C@@H](O)C[C@@]12[H])=O
English Name :(2R,6R)-6-((5R,7S,10S,13R,14R,15S,17R)-7,15-Dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-methyl-4-oxoheptanoic acid
MDL No. :MFCD26131275

Safety of Ganoderic acid A

Related Pathways of Ganoderic acid A

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HASMCs 10 µM 7 days To evaluate the effect of Ganoderic acid A on vascular smooth muscle cell calcification. Results showed that Ganoderic acid A significantly reduced calcium deposition. Theranostics. 2023 Feb 21;13(4):1325-1341.
RAW264.7 cells 10 µM 24 hours To evaluate the effect of Ganoderic acid A on foam cell formation. Results showed that Ganoderic acid A significantly reduced the number of foam cells. Theranostics. 2023 Feb 21;13(4):1325-1341.
Embryonic kidney cells 100μM 6 days Assess the inhibitory effect of GA-A on embryonic kidney cysts, showing significant reduction in cyst number and size. Acta Pharmacol Sin. 2020 Jun;41(6):782-790.
MDCK cells 6.25-100μM 24 hours Evaluate the inhibitory effect of GA-A on cyst growth in MDCK cells, showing significant inhibition without cytotoxicity. Acta Pharmacol Sin. 2020 Jun;41(6):782-790.
Primary B-cell lymphomas (TB#2759, TB#2952, TB#3284) 5-40μM 24 hours To evaluate the anti-proliferative activity of GA-A, results showed that GA-A significantly reduced cell viability in primary B-cell lymphomas with less effect on healthy B-cells. J Cell Biochem. 2015 Jan;116(1):102-14.
Non-Hodgkin’s lymphoma cells (DB, Toledo) 5-40μM 24 hours To evaluate the anti-proliferative activity of GA-A, results showed that GA-A significantly reduced cell viability with an IC50 of approximately 15μM. J Cell Biochem. 2015 Jan;116(1):102-14.
Human pre-B acute lymphocytic leukemia cells (NALM-6) 5-40μM 24 hours To evaluate the anti-proliferative activity of GA-A, results showed that GA-A significantly reduced cell viability with an IC50 of approximately 15-22μM. J Cell Biochem. 2015 Jan;116(1):102-14.
BV2 microglial cells 20 μM 6 hours Increases phosphorylation of Axl and Pak1, activating autophagy Int J Mol Sci. 2021 May 24;22(11):5559.
BV2 microglial cells 50 μg/ml 24 hours To evaluate the inhibitory effect of GAA on LPS-induced proliferation and activation of BV2 microglial cells. Results showed that GAA significantly suppressed LPS-induced BV2 microglial cells proliferation and activation, and promoted their conversion from M1 to M2 status. Neurochem Res. 2021 Jul;46(7):1725-1736.
SNU719 cells 0.49 mM 48 hours To evaluate the cytotoxic and apoptosis-inducing effects of GAA and QCT co-treatment on SNU719 cells. Results showed that the co-treatment significantly enhanced QCT-mediated cytotoxicity and apoptosis. Molecules. 2019 Oct 24;24(21):3834.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice KPKD mouse model Subcutaneous injection 50 mg/kg/d Once daily for 4 days Evaluate the inhibitory effect of GA-A on renal cysts in kPKD mice, showing significant reduction in cyst area and kidney index. Acta Pharmacol Sin. 2020 Jun;41(6):782-790.
C57BL/6 mice EL4 syngeneic mouse lymphoma model Intraperitoneal injection 60, 50 and 50 mg/kg body weight Injected once on days 10, 14, and 18 To evaluate the effect of GA-A on lymphoma growth and metastasis, results showed that GA-A significantly prolonged survival, reduced liver metastasis, and decreased the number of MDSCs. J Cell Biochem. 2015 Jan;116(1):102-14.
C57BL/6J mice Alzheimer's disease mouse model Oral gavage 100 mg/kg/d Once daily for 16 days Ameliorates cognitive deficiency, reduces Aβ42 levels in hippocampus, upregulates LC3B expression Int J Mol Sci. 2021 May 24;22(11):5559.
BALB/c mice OVA-induced asthma model Intraperitoneal injection 20, 40 mg/kg Once daily for 7 days Ganoderic acid A alleviates OVA-induced asthma inflammation in mice by inhibiting the TLR/NF-κB signaling pathway. Inflammation. 2021 Oct;44(5):1908-1915
BALB/c mice LPS-induced acute lung injury model Intraperitoneal injection 10 mg/kg and 20 mg/kg Single dose, lasted for 6 hours To investigate the protective effects of ganoderic acid A (GAA) on LPS-induced acute lung injury and its mechanism. The results showed that GAA significantly reduced lung wet-to-dry weight ratio, lung myeloperoxidase activity, attenuated pathological damages, increased superoxide dismutase activity, and decreased malondialdehyde content and proinflammatory cytokine levels in bronchoalveolar lavage fluid. Mechanistically, GAA inhibited LPS-induced inflammation by suppressing the Rho/ROCK/NF-κB pathway. Biosci Rep. 2019 May 23;39(5):BSR20190301

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.68mL

1.94mL

0.97mL

19.35mL

3.87mL

1.94mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories